Subtype-specific mutations drive relapse risk in most common childhood leukemia

Some cases of the most common childhood cancer, B-cell acute lymphoblastic leukemia (B-ALL), return after treatment—and genetic changes present from the start may help explain why. Scientists at St. Jude Children's Research Hospital and Seattle Children's Hospital, in collaboration with the Children's Oncology Group, found that mutations in a patient's original tumor can be associated with relapse risk, and that these changes differ by leukemia subtype. The findings, published in Blood, could help researchers better estimate and adjust for relapse risk before treatment begins.

Read it at Medical Xpress ↗

← Front page